MXPA04007007A - Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases. - Google Patents

Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases.

Info

Publication number
MXPA04007007A
MXPA04007007A MXPA04007007A MXPA04007007A MXPA04007007A MX PA04007007 A MXPA04007007 A MX PA04007007A MX PA04007007 A MXPA04007007 A MX PA04007007A MX PA04007007 A MXPA04007007 A MX PA04007007A MX PA04007007 A MXPA04007007 A MX PA04007007A
Authority
MX
Mexico
Prior art keywords
inhibitors
bicarbonate
exchanger
sodium
inflammatory diseases
Prior art date
Application number
MXPA04007007A
Other languages
Spanish (es)
Inventor
Niemeyer Andre
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA04007007A publication Critical patent/MXPA04007007A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to the use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thromobotic and inflammatory diseases. Said inhibitors of the cellular sodium-dependent chloride-bicarbonate-exchanger exhibit an inhibiting effect on the secretion of the Von Willebrand-factor. Said inhibitors can be used in the treatment of thrombotic and inflammatory diseases.
MXPA04007007A 2002-02-14 2003-02-05 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases. MXPA04007007A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10206354A DE10206354A1 (en) 2002-02-14 2002-02-14 Use of inhibitors of the sodium-dependent chloride-bicarbonate exchanger for the treatment of thrombotic and inflammatory diseases
PCT/EP2003/001100 WO2003068224A2 (en) 2002-02-14 2003-02-05 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases

Publications (1)

Publication Number Publication Date
MXPA04007007A true MXPA04007007A (en) 2004-10-11

Family

ID=27634996

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007007A MXPA04007007A (en) 2002-02-14 2003-02-05 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases.

Country Status (10)

Country Link
EP (1) EP1476154A2 (en)
JP (1) JP2005525338A (en)
AR (1) AR038837A1 (en)
AU (1) AU2003208792A1 (en)
BR (1) BR0307637A (en)
CA (1) CA2476454A1 (en)
DE (1) DE10206354A1 (en)
MX (1) MXPA04007007A (en)
TW (1) TW200306808A (en)
WO (1) WO2003068224A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202011111014U1 (en) 2010-11-05 2018-05-02 Senomyx, Inc. Compounds useful as modulators of TRPM8
BR112018006471B1 (en) 2015-10-01 2024-02-27 Senomyx, Inc COMPOUND, COMPOSITION, METHOD OF MODULATING THE MELASTIN MEMBER OF TRANSIENT RECEPTOR POTENTIAL CHANNEL 8 (TRPM8), METHOD OF MODULATING THE FEELING OF REFRESHMENT OF A COMPOSITION, AND METHOD OF INDUCING A FEELING OF REFRESHMENT IN A HUMAN OR ANIMAL

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741635A1 (en) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamides, process for their preparation and their use as a medicament
DE19804251A1 (en) * 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamides, process for their preparation and their use as a medicament
DE19820064A1 (en) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituted sulfonylcyanamides, process for their preparation and their use as a medicament
DE19832429A1 (en) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh New imidazolylmethyl-biphenyl-sulfonylcyanamides, are sodium-dependent bicarbonate/chloride exchanger inhibitors used e.g. for treating cardiovascular disorders such as cardiac infarction
DE19832428A1 (en) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh New imidazolylmethyl-biphenyl-sulfonylcyanamides, are sodium-dependent bicarbonate/chloride exchanger inhibitors used e.g. for treating cardiovascular disorders such as cardiac infarction

Also Published As

Publication number Publication date
JP2005525338A (en) 2005-08-25
DE10206354A1 (en) 2003-08-28
AU2003208792A1 (en) 2003-09-04
EP1476154A2 (en) 2004-11-17
CA2476454A1 (en) 2003-08-21
TW200306808A (en) 2003-12-01
WO2003068224A3 (en) 2003-12-24
AR038837A1 (en) 2005-01-26
WO2003068224A2 (en) 2003-08-21
BR0307637A (en) 2005-01-04

Similar Documents

Publication Publication Date Title
TW200501960A (en) Synergistic kits and compositions for treating cancer
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
SI2298338T1 (en) Lactoferrin compositions and methods of treatment of skin wounds
IL158559A0 (en) Acne treatment
TW200505434A (en) Therapeutic treatment
ATE376835T1 (en) USE OF FUCANES IN THE TREATMENT OF ADHESION, ARTHRITIS AND PSORIASIS
DE60330161D1 (en) RIFALAZIL FOR THE TREATMENT OF INFECTIONS WITH CLOSTRIDIUM DIFFICILE
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
DE60231050D1 (en) Use of totarol for the treatment of pruritus
EA200800766A1 (en) PI3K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
HK1073438A1 (en) Furin inhibitors for use in the treatment of fibrosis and scarring
ATE469659T1 (en) STIBOGLUCONATE SODIUM AND IL-2 FOR CANCER TREATMENT
FI20000635A0 (en) Use of COMT inhibitors as an analgesic
EP1546182A4 (en) Compositions and methods for the diagnosis and treatment of tumor
PL367287A1 (en) Use of proteasome inhibitors to treat dry eye disorders
ATE338566T1 (en) ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY FOR PREVENTING OR TREATING INFLAMMATORY-RELATED CARDIOVASCULAR DISEASES
MXPA04007007A (en) Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases.
RS95304A (en) New combination fortreating airway disorders
ZA9711468B (en) New use of comt inhibitors
TW200642688A (en) New use of PDE7 inhibitors
DE60109594D1 (en) R-ELIPRODIL FOR THE TREATMENT OF GLAUCOMA
ATE236633T1 (en) TOPICAL USE OF LOPERAMIDE TO TREAT MICROBIAL INFECTIONS
DE602004012759D1 (en) TREATMENT OF FIBROSES
MXPA04007387A (en) Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FA Abandonment or withdrawal